Johns Hopkins Medicine researchers reported clinical validation supporting the first FDA-cleared rapid urine test designed to aid diagnosis of invasive aspergillosis. The development targets a key diagnostic need: faster identification of a high-mortality fungal infection where delays can worsen outcomes. For clinical workflows, a urine-based assay that accelerates diagnostic certainty could enable earlier antifungal selection and tighter stewardship. The clearance also suggests a maturing pipeline for rapid diagnostics beyond respiratory samples.